UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Exploring the specificity of the PI3K family inhibitor LY294002

Biochemical journal, 2007-05, Vol.404 (1), p.15-21

2007

Volltextzugriff (PDF)

Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases

Current drug targets, 2010-11, Vol.11 (11), p.1430-1438

2010

Volltextzugriff (PDF)

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Journal of medicinal chemistry, 2008-09, Vol.51 (18), p.5522-5532

2008

Volltextzugriff (PDF)

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy

JCI insight, 2018-06, Vol.3 (11)

2018

Volltextzugriff (PDF)

Inhibition of Histone Deacetylase 6 Reveals a Potent Immunosuppressant Effect in Models of Transplantation

Transplantation, 2016-08, Vol.100 (8), p.1667-1674

2016

Volltextzugriff (PDF)

Functional characterization of a novel somatic oncogenic mutation of PIK3CB

Signal transduction and targeted therapy, 2017-01, Vol.2 (1), p.17063-17063, Article 17063

2017

Volltextzugriff (PDF)

Functionalised Polymers: Recent Developments and New Applications in Synthetic Organic Chemistry

Synthesis (Stuttgart), 1997-11, Vol.1997 (11), p.1217-1239

1997

Volltextzugriff (PDF)

Structural analysis of PI3-kinase isoforms: Identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors

Archives of biochemistry and biophysics, 2008-09, Vol.477 (2), p.404-410

2008

Volltextzugriff (PDF)

Functionalised Polymers in Organic Chemistry; Part 2

Synthesis (Stuttgart), 2000, Vol.2000 (8), p.1035-1074

2000

Volltextzugriff (PDF)

Abstract 3996: KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110p110 and HDAC6 with single-agent and combination activity

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3996-3996

Shuttleworth, Stephen J

2016

Volltextzugriff (PDF)

Abstract 3996: KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110β/p110δ and HDAC6 with single-agent and combination activity

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3996-3996

Shuttleworth, Stephen J.

2016

Volltextzugriff (PDF)

Discovery and optimization of a novel Neuromedin B receptor antagonist

Bioorganic & medicinal chemistry letters, 2009-08, Vol.19 (15), p.4264-4267

2009

Volltextzugriff (PDF)

Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements

Bioorganic & medicinal chemistry, 2011-01, Vol.19 (2), p.836-851

2011

Volltextzugriff (PDF)

Abstract 3639: Design and development of a novel series of orally active, selective PI3K-p110β/δ inhibitors for the treatment of solid and hematological cancers

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3639-3639

Shuttleworth, Stephen J.

2015

Volltextzugriff (PDF)

Abstract 3662: Design and development of a novel series of HDAC6-selective inhibitors for the treatment of hematological and solid tumors

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3662-3662

Shuttleworth, Stephen J.

2015

Volltextzugriff (PDF)

Abstract A68: Design and development of HDAC6-selective inhibitors for hematological cancer treatment and solid tumor immunotherapy

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A68-A68

Shuttleworth, Stephen J.

2015

Volltextzugriff (PDF)

Abstract LB-8: Design and development of a novel series of HDAC6-selective inhibitors for the treatment of cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.LB-8-LB-8

Shuttleworth, Stephen J.

2014

Volltextzugriff (PDF)

Abstract LB-7: Design and development of a novel series of orally active, selective PI3Kp110β/δ inhibitors for the treatment of cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.LB-7-LB-7

Shuttleworth, Stephen J.

2014

Volltextzugriff (PDF)

Design and synthesis of protein superfamily-targeted chemical libraries for lead identification and optimization

Current medicinal chemistry, 2005-01, Vol.12 (11), p.1239-1281

2005

Volltextzugriff (PDF)

Abstract B008: Design and development of a novel series of PI3K-p110beta/delta-selective inhibitors with combined tumor immunotherapeutic, growth inhibition, and anti-metastatic activity

Cancer immunology research, 2016-01, Vol.4 (1_Supplement), p.B008-B008

Shuttleworth, Stephen J.

2016

Volltextzugriff (PDF)

Abstract B009: Design and development of HDAC6-selective inhibitors for hematological cancer treatment and solid tumor immunotherapy

Cancer immunology research, 2016-01, Vol.4 (1_Supplement), p.B009-B009

Shuttleworth, Stephen J.

2016

Volltextzugriff (PDF)

Identification and optimization of novel partial agonists of Neuromedin B receptor using parallel synthesis

Bioorganic & medicinal chemistry letters, 2004-06, Vol.14 (12), p.3037-3042

2004

Volltextzugriff (PDF)

Parallel synthesis of isatin-based serine protease inhibitors

Bioorganic & medicinal chemistry letters, 2000-11, Vol.10 (22), p.2501-2504

2000

Volltextzugriff (PDF)

Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases

Current drug targets, 2010-07, Vol.999 (999), p.1-9

2010

Volltextzugriff (PDF)

1,2,3,4-Tetrahydro-γ-carbolinium salts: novel reactions with thiols, mediated by polymer-supported reagents

Tetrahedron letters, 2004-06, Vol.45 (24), p.4781-4783

2004

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(70)

Publikationsform

Sprache

Englisch
(81)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cheminform
(9)
Cancer Research
(7)
Tetrahedron Letters
(7)
Bioorganic & Medicinal Chemistry Letters
(5)
The Journal Of Physiology
(4)
Biochemical Journal
(3)
Current Drug Targets
(3)
Journal Of Medicinal Chemistry
(3)
Synthesis
(3)
Blood
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Exploring the specificity of the PI3K family inhibitor LY294002

Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy

Inhibition of Histone Deacetylase 6 Reveals a Potent Immunosuppressant Effect in Models of Transplantation

Functional characterization of a novel somatic oncogenic mutation of PIK3CB

Functionalised Polymers: Recent Developments and New Applications in Synthetic Organic Chemistry

Structural analysis of PI3-kinase isoforms: Identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors

Functionalised Polymers in Organic Chemistry; Part 2

Abstract 3996: KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110p110 and HDAC6 with single-agent and combination activity

Abstract 3996: KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110β/p110δ and HDAC6 with single-agent and combination activity

Discovery and optimization of a novel Neuromedin B receptor antagonist

Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements

Abstract 3639: Design and development of a novel series of orally active, selective PI3K-p110β/δ inhibitors for the treatment of solid and hematological cancers

Abstract 3662: Design and development of a novel series of HDAC6-selective inhibitors for the treatment of hematological and solid tumors

Abstract A68: Design and development of HDAC6-selective inhibitors for hematological cancer treatment and solid tumor immunotherapy

Abstract LB-8: Design and development of a novel series of HDAC6-selective inhibitors for the treatment of cancer

Abstract LB-7: Design and development of a novel series of orally active, selective PI3Kp110β/δ inhibitors for the treatment of cancer

Design and synthesis of protein superfamily-targeted chemical libraries for lead identification and optimization

Abstract B008: Design and development of a novel series of PI3K-p110beta/delta-selective inhibitors with combined tumor immunotherapeutic, growth inhibition, and anti-metastatic activity

Abstract B009: Design and development of HDAC6-selective inhibitors for hematological cancer treatment and solid tumor immunotherapy

Identification and optimization of novel partial agonists of Neuromedin B receptor using parallel synthesis

Parallel synthesis of isatin-based serine protease inhibitors

Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases

1,2,3,4-Tetrahydro-γ-carbolinium salts: novel reactions with thiols, mediated by polymer-supported reagents

Suchergebnisse filtern